03.28.2019

GE Healthcare and SonoMotion sign a second co-development agreement and expand their strategic relationship with an updated OEM agreement.

03.26.2019

SonoMotion receives Health Canada ITA approval to initiate its Break Wave™ First-In-Human clinical trial in Canada.

12.14.2018

SonoMotion receives FDA IDE approval to initiate its Break Wave™ First-In-Human clinical trial in the United States.

10.31.2017

GE Healthcare and SonoMotion establish a strategic partnership and sign a definitive OEM agreement and co-development agreement.

08.01.2017

SonoMotion receives a $1.0M SBIR Commercial Readiness Program grant from the NIH for the development of Stone Clear™.

04.07.2017

SonoMotion closes on a $4.6M Series-A round led by MedVenture Partners Inc. and with a significant participation by Bioventures Investors.